DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dy
DYN Dyne Therapeutics announces U.S. FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dystrophy (dmd) Dyne Therapeutics, - FDA grants priority review with pdufa date January 21, 2027
DYN Dyne Therapeutics announces U.S.
FDA Acceptance of Biologics license application (bla) for z-rostudirsen in exon 51 duchenne muscular dystrophy (dmd) Dyne Therapeutics, - FDA grants priority review with pdufa date January 21, 2027